ArticleFrontiers in immunology2026
Efgartigimod for acute attacks of brainstem MOGAD followed by mycophenolate mofetil maintenance: a case report.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is an autoimmune inflammatory demyelinating disorder of the central nervous system with a broad clinical spectrum that includes brainstem syndromes. Evidence supporting neonatal Fc receptor (FcRn) inhibition in MOGAD remains limited. Case presentation: A 37-year-old woman presented with a MOGAD-associated brainstem syndrome characterized by diplopia, ocular-motor abnormalities, right facial weakness, and gait instability. Brain MRI demonstrated a lesion in the right middle cerebellar peduncle near the fourth ventricle. CSF analysis showed 2 leukocytes/µL, 0 erythrocytes/µL, normal protein (0.328 g/L), a type II oligoclonal-band pattern, and an elevated IgG index of 1.8 (reference value, <0.7), supporting intrathecal IgG synthesis. Serum MOG-IgG was positive by live cell-based assay. High-dose corticosteroids were discussed, but the patient declined them because of concerns regarding adverse effects. IVIG was subject to intermittent local shortage and substantial financial burden, while PLEX was considered disproportionate to the clinical severity. The patient received individualized off-label intravenous efgartigimod (20 mg/kg on Days 1 and 5) and improved clinically. After the second relapse, the same efgartigimod regimen was repeated, and low-dose oral prednisone and MMF were initiated for relapse prevention. Prednisone was discontinued approximately 5 months after initiation, whereas MMF was continued as maintenance therapy. At follow-up approximately 18 months after discharge, the patient was clinically asymptomatic. Discussion: This case documents a recognized brainstem MOGAD presentation with clinical improvement temporally associated with individualized off-label FcRn inhibition. Interpretation should consider the single-case design, absence of a comparator, rehabilitation, low-dose prednisone and MMF initiated for relapse prevention, and the natural course of the disease. This observation provides preliminary clinical context for prospective evaluation of FcRn inhibition but is insufficient to establish efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.